Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00054457 · ClinicalTrials.gov registry record · Phase 2

Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
46
Enrollment target
20
Study locations

NCT00054457 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 46 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00054457, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
46 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study of the effectiveness of combining docetaxel with capecitabine in treating patients who have metastatic cancer of the stomach or gastroesophageal junction.

Conditions Studied

Gastric Cancer Esophageal Cancer

Interventions

  • DRUG docetaxel
  • DRUG capecitabine

Study Locations (20)

Kansas

  • Cancer Center of Kansas, PA - Chanute - Chanute
  • Cancer Center of Kansas, PA - Dodge City - Dodge City
  • Cancer Center of Kansas, PA - El Dorado - El Dorado
  • Cancer Center of Kansas, PA - Kingman - Kingman
  • Southwest Medical Center - Liberal
  • Cancer Center of Kansas, PA - Newton - Newton
  • Cancer Center of Kansas, PA - Parsons - Parsons
  • Cancer Center of Kansas, PA - Pratt - Pratt
  • Cancer Center of Kansas, PA - Salina - Salina
  • Cancer Center of Kansas, PA - Wellington - Wellington
  • Associates in Womens Health, PA - North Review - Wichita
  • Cancer Center of Kansas, PA - Medical Arts Tower - Wichita
  • Cancer Center of Kansas, PA - Wichita - Wichita
  • CCOP - Wichita - Wichita
  • Via Christi Cancer Center at Via Christi Regional Medical Center - Wichita
  • Cancer Center of Kansas, PA - Winfield - Winfield

Minnesota

  • Fairview Ridges Hospital - Burnsville
  • Mercy and Unity Cancer Center at Mercy Hospital - Coon Rapids
  • Fairview Southdale Hospital - Edina
  • Mercy and Unity Cancer Center at Unity Hospital - Fridley

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2003-09
Est. Completion 2008-02
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00054457

The ClinicalTrials.gov registry entry for NCT00054457 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.

NCT00054457 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00054457 about?

NCT00054457 is a clinical study titled "Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study of the effectiveness of combining docetaxel with capecitabine in treating patients who hav...

What is the current status of trial NCT00054457?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2003-09. Estimated completion is 2008-02.

What conditions does trial NCT00054457 study?

This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer.

What interventions are being tested in trial NCT00054457?

The interventions under investigation include: docetaxel (DRUG), capecitabine (DRUG).

Who is sponsoring clinical trial NCT00054457?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00054457 being conducted?

This trial has 20 study locations across Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Esophageal Cancer

All registered trials for this condition

Kansas

All trials with a study site in Kansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.